Quarterly ResultAug 13, 2026, 04:02 PM
MDxHealth Q2 Revenue +16% to $27.2M; Net Loss $9.5M
AI Summary
MDxHealth announced its second quarter 2026 financial results, reporting a 16% increase in revenue to $27.2 million. However, the company experienced a significant rise in operating loss to $5.1 million and net loss to $9.5 million, primarily due to increased operating expenses related to the ExoDx acquisition. The company also successfully completed the discontinuation of its Resolve mdx business and secured $20 million in gross proceeds from a registered direct placement, strengthening its balance sheet.
Key Highlights
- Q2 2026 revenue increased 16% to $27.2 million over prior year.
- Q2 2026 operating loss was $5.1 million, up 236% from $1.5 million in Q2 2025.
- Q2 2026 net loss increased 36% to $9.5 million.
- Q2 2026 adjusted EBITDA was $(2.3) million, down from $1.1 million in Q2 2025.
- Successfully completed discontinuation of Resolve mdx business in Q2 2026.
- Executed a registered direct placement for $20 million gross proceeds on August 11, 2026.
- Period-end cash and cash equivalents were $19.2 million, pro-forma $39.2 million.
Price Impact
More from MDXH